Core Viewpoint - The collaboration between Deqi Pharmaceutical and Junshi Biosciences aims to explore the synergistic potential of their respective drugs, ATG-037 and JS207, in treating tumor patients in mainland China, particularly in the context of overcoming resistance to immune checkpoint inhibitors [1] Group 1: Company Developments - Deqi Pharmaceutical's stock rose by 6.4%, reaching HKD 3.66, with a trading volume of HKD 13.326 million [1] - The company announced a clinical collaboration agreement with Junshi Biosciences to jointly investigate the combination therapy of ATG-037, an oral CD73 small molecule inhibitor, and JS207, a dual-specific antibody targeting PD-1/VEGF [1] Group 2: Industry Context - The collaboration addresses a significant clinical challenge where resistance to immune checkpoint inhibitors (CPI) has become prevalent [1] - ATG-037 has demonstrated strong potential in reversing resistance in Phase I trials when used in combination with CPIs [1] - The partnership aims to validate the synergistic effects of the two innovative drugs and seeks to extend overall survival (OS) for cancer patients through a "triple-axis" strategy involving "immunotherapy + anti-angiogenesis + adenosine inhibition" [1]